Paul Cloos, PhD

Chief Executive Officer (Co-Founder)

LinkedIn

Paul is a scientist–entrepreneur with over 20 years of experience in drug discovery, translational research, and company creation. He co-founded Epitherapeutics, one of Denmark’s first epigenetics start-ups, which Gilead later acquired. At Novo Holdings SeedLab, he spearheads due diligence and incubation of early-stage biotech ventures, combining scientific excellence with strategic project leadership and investor engagement.

With over 40 scientific publications, 10 patent families, and leadership roles spanning academia, biotech, and pharma, Paul combines deep scientific expertise with strategic insight. He has secured multi-million-euro partnerships, advised investors, and mentored cross-disciplinary teams, making him a key driver of innovation at the interface of science and business.

Summary